How Will Skyrizi and Rinvoq Shape AbbVie's Q1 Immunology Sales?

ABBV heads into Q1 earnings with Skyrizi and Rinvoq in focus as Humira declines, while growth from new indications and market share gains is under watch.

AbbVie ABBV is set to report first-quarter 2026 results on April 29, with investor focus likely to remain on its immunology segment. Following the loss of exclusivity (LoE) for its flagship drug, Humira, the company has been leaning heavily on Skyrizi and Rinvoq to drive growth.

AbbVie successfully launched Skyrizi and Rinvoq across Humira's major indications, and a distinct new indication, atopic dermatitis. Both drugs have delivered strong performance across approved indications, especially in the popular inflammatory bowel disease (IBD) space, which includes ulcerative colitis (UC) and Crohn’s disease (CD).

Continued momentum from these therapies, supported by market share gains and recent label expansions — including Skyrizi in UC and Rinvoq in giant cell arteritis (GCA) — is expected to drive immunology sales in the quarter. The Zacks Consensus Estimate for Skyrizi and Rinvoq sales is pegged at $4.43 billion and $2.07 billion, respectively, for the to-be-reported quarter, representing growth from the year-ago period.

Meanwhile,........

© Quartz